

# Insights on Cardiac Problems in COVID Patients

Lisa Andrew\*

Department of Cardiology, University of Helsinki, Yliopistonkatu 4, 00100 Helsinki, Finland

## Description

The coronavirus disease of 2019 (COVID-19), which causes severe acute respiratory sickness, is caused by the coronavirus 2 (SARS-CoV-2). Cardiovascular problems, in addition to systemic inflammation and pulmonary difficulties, may ensue, leading in severe morbidity and mortality. After nearly a year of exposure to the COVID-19 (SARS-CoV-2) virus, it has been discovered that certain COVID-19 (SARS-CoV-2) patients have developed post COVID symptoms such as chronic coughs, cognitive difficulties, and other complaints. Long-haul drivers appeared to be suffering from heart problems as well.

In 2021, one of the most pressing cardiology issues will be determining the long-term consequences of coronavirus. Because COVID kills cardiomyocytes, cadaver studies on COVID patients have raised concerns about long-term heart damage. However, it has been raised the question of what the long-term consequences of this heart injury will be. Clinical studies have also revealed a relationship between COVID-19 and cardiovascular disease. Despite the fact that COVID-19 can cause myocardial damage, arrhythmia, and acute coronary syndrome, patients who have pre-existing cardiovascular disease appear to have worse outcomes and a higher risk of mortality [1-3]. COVID-19 causes both direct and indirect harm to the heart. Myocarditis is caused when a virus infects heart cells and causes direct cardiac damage (cell inflammation). This inflammation can range from mild to severe, resulting in reduced heart function, irregular heart rhythms, and the risk of sudden cardiac death.

To seek for evidence of heart injury or malfunction, they perform blood tests for cardiac biomarkers, an ECG, and echocardiography with strain studies. According to the results of this cardiac examination, many of these patients have sustained heart damage as a result of their COVID-19 infection. Despite testing negative for the virus, patients have underlying heart damage that is now causing symptoms. Neutrophils have long been considered of being uninvolved bystanders or biomarkers for heart disease. Neutrophils, on the other hand, have been proven in recent studies to have an important role in cardiovascular inflammation and repair. The effects of well-known and novel cardiovascular risk factors on neutrophil production and function. The current state of knowledge about neutrophil contribution to atherosclerosis stages such as atherogenesis, plaque instability, and plaque erosion is next discussed. In the context of cardiovascular repercussions of atherosclerosis, we highlight the dual role of neutrophils in pathogenic and repair processes in stroke, heart failure, myocardial infarction, and neointima formation. Finally, we emphasise the need of comprehending neutrophil functions in cardiovascular homeostasis and disease in order to create therapy options that target neutrophil numbers, functional status, and effector pathways. The coronavirus disease of 2019 (COVID-19) is caused by the coronavirus 2 that produces severe acute respiratory illness (SARS-CoV-2).

**Address for Correspondence:** Lisa Andrew, Department of Cardiology, University of Helsinki, Yliopistonkatu 4, 00100 Helsinki, Finland, E-mail: LisaAndrew99@gmail.com

**Copyright:** © 2022 Andrew L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Received:** 07 September, 2022, Manuscript No. jchd-23-86248; **Editor assigned:** 08 September, 2022, Pre QC No. P-86248; **Reviewed:** 21 September, 2022, QC No. Q-86248; **Revised:** 26 September, 2022, Manuscript No. R-86248; **Published:** 03 October, 2022, DOI: 10.37421/0974-7230.2022.6.155

In addition to systemic inflammation and pulmonary issues, cardiovascular abnormalities might occur, resulting in significant morbidity and mortality. With almost a year of experience with the COVID-19 (SARS-CoV-2) virus, it has been observed that some COVID-19 (SARS-CoV-2) patients develop post-COVID symptoms after they recover from the illness, including chronic coughs, cognitive impairments, and other issues. These long-haul drivers appeared to have heart problems as well. Determine the long-term implications of coronavirus will likely be one of the most important cardiology problems in 2021. COVID patient cadaver studies also raised concerns regarding long-term heart damage since COVID kills cardiomyocytes [4,5]. However, the question of what the long-term ramifications of this cardiac injury will be has been raised. Clinical studies have also revealed a relationship between COVID-19 and cardiovascular disease.

Despite the fact that COVID-19 can cause myocardial injury, arrhythmia, and acute coronary syndrome, patients with COVID-19 appear to have worse outcomes and a higher chance of death if they have pre-existing cardiovascular disease. COVID-19 affects the heart both directly and indirectly. When a virus infects heart cells and causes myocarditis, it causes direct cardiac damage (cell inflammation). This inflammation can be minor to severe, leading in decreased heart function, abnormal heart rhythms, and the possibility of abrupt cardiac death. They use blood testing for cardiac biomarkers, an ECG, and an echocardiography with strain studies to look for signs of heart injury or malfunction. According to this cardiac work-up, many of these patients have had heart injury as a result of COVID-19 disease. Patients have underlying cardiac damage that is now causing symptoms, even after testing negative for the virus.

## Acknowledgement

None.

## Conflict of Interest

Authors declare no conflict of interest.

## References

1. Mattar, Ahmed, David Carlston, Glen Sariol, and Tongle Yu, et al. "The prevalence of obesity documentation in primary care electronic medical records." *App Clin Inf* 26 (2017): 67-79.
2. Mahmood, Syed S., Daniel Levy, Ramachandran S. Vasan, and Thomas J. Wang. "The Framingham Heart Study and the epidemiology of cardiovascular disease: A historical perspective." *Lancet* 383 (2014): 999-1008.
3. Balakumar P, Maung UK, and Jagadeesh G. "Prevalence and prevention of cardiovascular disease and diabetes mellitus." *Pharmacol Res* 113 (2016): 600-609.
4. Danaei, Goodarz, Carlene MM Lawes, Stephen Vander Hoorn, and Christopher JL Murray. "Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: Comparative risk assessment." *Lancet* 368 (2006): 1651-1659.
5. Shu Jun, and Gaetano Santulli. "Update on peripheral artery disease: epidemiology and evidence-based facts." *Atherosclerosis* 275 (2018): 379-381.

**How to cite this article:** Andrew, Lisa. "Insights on Cardiac Problems in COVID Patients." *J Coron Heart Dis* 6 (2022):155